Ron

Entrepreneurship: Fundamentals for Academics Starting a Biotech Company

We just passed the 40th anniversary of the biotech industry, a birth made possible by the confluence of a seminal patent in recombinant DNA technology, the successful IPO of the first biotech company Genentech, validation of a Nobel Prize in Medicine and Physiology for recombinant DNA technology, and key legislation empowering academic institutions to commercialize […]

Entrepreneurship: Fundamentals for Academics Starting a Biotech Company Read More »

$74 million Series B Funding for Tvardi Therapeutics

As a Co-Founder and former Chairman of the Board I’m excited to announce that we’ve closed a $74 million Series B round of financing at Tvardi Therapeutics. Proceeds from this financing will be used to advance Tvardi’s product candidates through multiple clinical data readouts in mid-stage trials for cancer and fibrosis. Tvardi Therapeutics, Inc. (“Tvardi”),

$74 million Series B Funding for Tvardi Therapeutics Read More »

Ron DePinho one of several honored with 2020 AACR Team Science Awards

The American Association for Cancer Research (AACR) is recognizing the founding members of The Cancer Genome Atlas (TCGA) and the current project team with 2020 AACR Team Science Awards. These teams will be honored during the AACR Virtual Annual Meeting II on June 24. The Cancer Genome Atlas was launched in 2006 as a joint

Ron DePinho one of several honored with 2020 AACR Team Science Awards Read More »

KRLD Radio Interview

Some Covid Survivors Face Long-Term Consequences HOUSTON (1080 KRLD)- The majority of people who get the virus will get well without serious complications. Some may not even show symptoms. But a small minority, about five percent, do get seriously ill and require hospitalization. That group is at risk for developing pulmonary fibrosis, which is a

KRLD Radio Interview Read More »

Overcoming Covid-19 is Just the First Hurdle of a Much Longer Journey

While a longer recovery course might be expected for someone such as Herbert who faced a more severe illness, there’s also concern for more permanent lung damage, according to Dr. Ronald DePinho* – co-founder of Tvardi Therapeutics. DePinho is particularly worried that the immune response to Covid-19 may cause irreversible scarring known as pulmonary fibrosis.

Overcoming Covid-19 is Just the First Hurdle of a Much Longer Journey Read More »

Immune cells enables escape from oncogenic KRAS dependency in pancreatic cancer

Tumor microenvironment remodeling enables bypass of oncogenic KRAS dependency in pancreatic cancer. Authors: Pingping Hou, Avnish Kapoor, Qiang Zhang, Jiexi Li, Chang-Jiun Wu, Jun Li, Zhengdao Lan, Ming Tang, Xingdi Ma, Jeffrey J Ackroyd, Raghu Kalluri, Jianhua Zhang, Shan Jiang, Denise J. Spring, Y. Alan Wang and Ronald A. DePinho Abstract Oncogenic KRAS (KRAS*) is

Immune cells enables escape from oncogenic KRAS dependency in pancreatic cancer Read More »

COVID-19

At this moment, humanity is battling the novel coronavirus (COVID-19). Many loved ones have been directly affected by contracting the disease, and others indirectly by economic hardship. With COVID-19, immunocompromised individuals such as cancer patients must stay vigilant in protecting themselves. Standard recommendations to prevent infection spread include regular hand washing, covering mouth and nose

COVID-19 Read More »

Get Insights From Ron

Sign up for the latest news and updates from Ron DePinho, MD